MedTrace Logo

Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin Treat Congenital Hypogonadotropic Hypogonadism

NCT02880280 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-08-26

No results posted yet for this study

Summary

Observe the therapeutic efficacy of human menopausal gonadotropin combining with human chorionic gonadotropin in adolescent boys with congenital hypogonadotropic hypogonadism.

Conditions

  • Kallmann Syndrome
  • Hypogonadotropic Hypogonadism

Interventions

DRUG

Human Menopausal Gonadotropin

Human Menopausal Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers

DRUG

Human Chorionic Gonadotropin

Human Chorionic Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers

Sponsors & Collaborators

  • Beijing Children's Hospital

    lead OTHER

Principal Investigators

  • Chunxiu Gong, doctor · Beijing Children's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
138 Months
Max Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-31
Primary Completion
2017-08-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02880280 on ClinicalTrials.gov